Therefore the CPMP considered that the benefit/ risk balance of loratadine containing medicinal products is favourable for the indication “ relief of symptoms associated with Allergic Rhinitis and Chronic Idiopathic Urticaria” and recommended the maintenance or the granting of the Marketing Authorisations according to the Summary of Product Characteristics as set out in Annex III of the CPMP Opinion with emphasis to the following: